Breakthrough in Immunotherapy for Kidney Cancer

Researchers at the University of California, Los Angeles (UCLA), have developed a novel immunotherapy approach that uses specially engineered immune cells to attack kidney cancer tumors. The innovative "off-the-shelf" therapy, called AlloCAR70-NKT, has shown promising results in preclinical models, demonstrating a multi-pronged attack against kidney cancer. This approach has the potential to improve outcomes, reduce complications, and expand access to treatment for patients with limited options.

Key Takeaways:

• The AlloCAR70-NKT therapy is an "off-the-shelf" approach that uses specially engineered immune cells to attack kidney cancer tumors without the need for customization for each patient.
• The therapy targets CD70, a protein commonly found on kidney cancer cells, using a chimeric antigen receptor (CAR) that is resistant to immune rejection and remains active in the tumor environment.
• The AlloCAR70-NKT cells demonstrated a multi-pronged attack against kidney cancer, including direct killing of cancer cells, disruption of the tumor's microenvironment, and elimination of CD70-positive host immune cells.
• The therapy has shown early promise in preclinical models and has the potential to offer a new lifeline for patients with metastatic kidney cancer, which has a five-year survival rate of just 12%.
• The researchers engineered natural killer T (NKT) cells derived from stem cells to express the CAR, which targets CD70, overcoming challenges in cancer immunotherapy, such as limited durability and poor tumor penetration.
• The therapy was developed by researchers at the UCLA Health Jonsson Comprehensive Cancer Center and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research.

Statistics:

• 12%: The five-year survival rate for patients with metastatic kidney cancer.
• Unknown: The number of patients with metastatic kidney cancer who are currently eligible for the AlloCAR70-NKT therapy.
• 2025: The year of the study's publication in Cell Reports Medicine.
• 100%: The percentage of AlloCAR70-NKT cells that were designed to resist immune rejection and remain active in the tumor environment.

Sources:

• Cell Reports Medicine (2025)
• UCLA Health Jonsson Comprehensive Cancer Center
• Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
• California Institute for Regenerative Medicine
• Parker Institute for Cancer Immunotherapy (PICI)
• Kidney Cancer Research Program Award from the Department of Defense